Showing results (951-960 of 1,241) with videos related to
Sort By:
Pageof 125
BMJ Open|August 8, 2024
Impact of aspirin dose according to race in secondary prevention of atherosclerotic cardiovascular disease: a secondary analysis of the ADAPTABLE randomised controlled trialGuillaume Marquis-Gravel, Hillary Mulder, Lisa M Wruck, et al.Journal of the American College of Cardiology|March 20, 2024
Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart FailureDavid A Morrow, Eric J Velazquez, Akshay S Desai, et al.JACC. Heart Failure|December 3, 2014
Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injuryTariq Ahmad, Teresa Wang, Emily C O'Brien, et al.Journal of the American College of Cardiology|June 24, 2017
Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF TrialStephen J Greene, Adrian F Hernandez, Allison Dunning, et al.Circulation. Heart Failure|September 15, 2016
Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)Stephen J Greene, Adrian F Hernandez, Jie-Lena Sun, et al.The American Journal of Cardiology|November 5, 2019
Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF)Erika M Giblin, Kirkwood F Adams, Larry Hill, et al.Journal of the American Heart Association|February 5, 2019
Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart FailureNancy Luo, Steven J Lippmann, Robert J Mentz, et al.Journal of the American Heart Association|December 11, 2019
Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines-Heart FailureJacob P Kelly, Adam D DeVore, JingJing Wu, et al.European Journal of Heart Failure|May 17, 2021
Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trialAdriaan A Voors, Hillary Mulder, Eugene Reyes, et al.Journal of Cardiac Failure|July 4, 2021
Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) TrialRobert J Mentz, Hillary Mulder, Arend Mosterd, et al.Pageof 125